Most Popular Angioplasty Web Site
supported by Volcano Corporation
Volcano Corporation Announces Schedule of Events for TCT (Transcatheter Cardiovascular Therapeutics Conference) 2008
Live Case Transmissions and Symposia to Highlight New Product Launches and
Clinical Utility of Volcano Technologies including FFR, IVUS, VH IVUS, OCT
and Forward-Looking IVUS

external sites:
Volcano Corporation

October 13, 2008 / Washington DC -- Volcano Corporation (Nasdaq: VOLC) today announced its participation in the 2008 TCT Conference in Washington, D.C. from October 12-17. Volcano programming includes PROSPECT, IBIS II and VH Registry clinical study data, live case broadcasts and an expanded booth presence with live demonstrations, training and education. Volcano will also host its inaugural TCT evening symposium highlighting various product launches, including the Volcano s5(TM) family of IVUS and FFR capable consoles, the Revolution(R) 45 MHz high-frequency IVUS catheter, and the official launch of the new PrimeWire(TM) FFR Pressure Guidewire. Volcano is dedicated to making intravascular imaging and assessment faster and easier than ever before by offering the only integrated imaging console capable of phased array IVUS, rotational IVUS and integrated FFR, all on the same system.

Product Launches
Volcano is pleased to announce the launch of the new PrimeWire Pressure Guidewire, which is compatible with Volcano's s5 family of integrated imaging consoles. "The launch of the PrimeWire underlines Volcano's commitment to this very important Functional Measurement (FM) market. Groundbreaking data presented over the past year, including the DEFER study five year follow-up and the FAME study which will be presented at this year's TCT, highlight the importance of only treating truly ischemic lesions, a characteristic that can often be missed with angiography alone. These powerful data, combined with the launches of our new PrimeWire and s5 console with IVUS and FFR, will only fuel FFR education and usage, and Volcano will continue to make strides toward market leadership," Scott Huennekens, president and CEO of Volcano.

Hospitals with Volcano's s5 and s5i imaging consoles in the U.S. and Europe can now acquire the FFR functionality to support the PrimeWire and add this important tool to their existing IVUS system and workflow.

Volcano also offers two different IVUS platforms that are compatible with our newest integrated IVUS consoles. Revolution is Volcano's first high- frequency coronary imaging catheter and operates at a 45 MHz frequency, providing increased resolution and clarity in the near-field. The Revolution can accommodate a 15 cm pullback inside of a stationary, protective sheath, and also includes a reinforced proximal shaft, robust locking mechanism, and RFID catheter-to-console communication that are designed for consistent, reliable image quality.

Joe Burnett, associate vice president, marketing commented, "Earlier- generation consoles included only one of the three technologies now available on the s5. If a hospital wanted to equip a new lab with all three technologies, they would have to acquire three separate consoles, each with a different measurement modality, training requirements and data storage protocols. The Volcano s5 can now accommodate the three primary intravascular diagnostic tools in regular use by cardiologists today (high frequency rotational IVUS, fast and simple digital IVUS, and pressure-based FFR guidewires) on a single platform, making modern day imaging consoles more flexible than ever before."

Evening Symposium
Volcano's first-ever TCT evening symposium will focus on "The future of intravascular imaging: How IVUS, FFR, VH IVUS, CTO Imaging and OCT can improve patient outcomes." Speakers for this symposium include Alex Abizaid, M.D., Augusto Pichard, M.D., Matthew Price, M.D. Mort Kern, M.D., David Williams, M.D., Guilio Guagliumi M.D., Gary Mintz, M.D. and Steven Marso, M.D. The event will be held in the Renaissance ballroom at the Marriott Renaissance Hotel near the Convention Center on Tuesday, October 14. A reception will start at 7:00 PM, and the symposium begins at 8:00 PM.

Live Case Transmissions
During the week of TCT, Volcano will collaborate with physicians globally to provide a full schedule of live case demonstrations of Volcano's innovative intravascular imaging and intracoronary physiology products. This will include transmissions featuring Volcano's fast and easy-to-use s5 family of IVUS consoles, including Volcano's s5i customized integrated cath lab format and GE Healthcare's unique-in-the-industry Innova IVUS system.

Clinical Trial Updates
On Monday, October 13, a session chaired by Valentin Fuster and Attilio Maseri will focus on Vulnerable Plaque Trials and Therapies: Focusing a Subspecialty, Part I: Natural History and Medical Therapy in Room 152A. The program includes presentations on the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) and IBIS II (Integrated Biomarker and Imaging Study) trials.

Gregg W. Stone, M.D., Principle Investigator of PROSPECT will present baseline demographic and imaging data from the complete set of almost 700 patients. "As the first prospective natural history study examining whether novel blood and imaging tests are able to identify patients at risk for future death and heart attack, PROSPECT promises to provide groundbreaking data critical to understanding the progression of coronary artery disease, and represents the first step toward identifying patients at high risk who may benefit from preventative therapies," said Dr. Stone. PROSPECT is a global study with over 40 centers participating worldwide, aimed at determining the likelihood of specific plaque types to cause heart attacks.

Following the PROSPECT presentation, Patrick Serruys, M.D., Ph.D. will be presenting results from GlaxoSmithKline's IBIS-2 trial. In the study, Volcano's VH(R) IVUS technology demonstrated and quantified compositional changes in atherosclerotic plaque that occurred over time. VH(R) IVUS also showed compositional changes in the placebo group that suggest continued progression of necrotic core despite standard of care medical therapy. Use of the novel Lp-PLA2 inhibitor, darapladib, plus standard of care therapy appeared to prevent this progression.

The Volcano VH Registry, aimed at correlating plaque characteristics with patient demographics, clinical presentation, and cardiac risk factors, has now completed enrollment of over 3,000 patients worldwide. Seven separate abstracts pooled from the VH Registry data will be presented throughout the week of TCT highlighting correlations in diverse patient subsets.

Expanded Booth Presence to Demonstrate New Products
Volcano will feature an expanded product expo area in the commercial exhibit spaces at TCT. Please visit us in booth #1006 at TCT for a complete tour of Volcano's newest intravascular imaging and intracoronary physiology products.

About Volcano Corporation
Volcano Corporation (VOLC), which completed its IPO in June 2006, offers a broad suite of devices that facilitate endovascular procedures. Volcano's products enhance the diagnosis of vascular and structural heart diseases and guide optimal therapies. The company's IVUS (intravascular ultrasound) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab and single-use phased array and rotational IVUS imaging catheters. Volcano also has unique advanced functionality options like VH tissue characterization and IVUS and angiography co-registration. Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires. Currently, more than 2,000 Volcano IVUS and FM systems are installed worldwide, with nearly half of its revenues coming from outside the United States. For more information, visit the company's website at

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release regarding Volcano's business that are not historical facts may be considered forward-looking statements, including statements regarding the ability of VH(R) IVUS to measure the effects of investigational compounds, the ability to identify and characterize composition and to define patient strategy to improve patient outcomes. Forward-looking statements involve risks and uncertainties and are based on management's current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including the risks and uncertainties related to the results of clinical studies and other factors discussed in Volcano's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the time they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, changed assumptions or otherwise. Actual results or experience could differ materially from the forward-looking statements.

Source: Volcano Corporation